Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.

Pegcetacoplan Injection Mechanism of Action Video for GA

May 30, 2025/in Uncategorized/by katarina chin
Read more
https://apellismedicalhub.com/wp-content/uploads/2022/12/apellis-medical-hub.png 0 0 katarina chin https://apellismedicalhub.com/wp-content/uploads/2022/12/apellis-medical-hub.png katarina chin2025-05-30 11:24:102025-05-30 11:24:10Pegcetacoplan Injection Mechanism of Action Video for GA

Pegcetacoplan Injection Mechanism of Action Video for PNH

June 26, 2023/in Uncategorized/by katarina chin
Read more
https://apellismedicalhub.com/wp-content/uploads/2022/12/apellis-medical-hub.png 0 0 katarina chin https://apellismedicalhub.com/wp-content/uploads/2022/12/apellis-medical-hub.png katarina chin2023-06-26 05:55:232025-05-27 12:00:06Pegcetacoplan Injection Mechanism of Action Video for PNH

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 08/25 MED-US-CORP-22-00001 v14.0
Scroll to top

Geographic Atrophy Risk Calculator Important Usage Information

Intended Use

•  This Geographic Atrophy (GA) Risk Calculator is only intended for disease state awareness and for use by an eye doctor to understand the factors for disease progression. This is not a diagnostic tool or a tool to assist in treatment selection.

•  All decisions about patient care and diagnosis shall be made by a patient’s physician using his or her independent clinical judgment.

•  The GA Risk Calculator predicts a potential 5-year risk of outcomes for a GA patient (time to severe visual impairment (Snellen 20/200) and time to subfoveal involvement). This tool was developed utilizing risk equations using retrospective electronic health records of GA data from Cleveland Clinic patients (n=410). Statistical tests identified the most prominent predictors for time to severe visual impairment prediction as baseline visual acuity, subfoveal lesion, age, sex, smoking, fellow eye GA and select comorbidities. Validation was conducted using the Sham arms of Oaks (ClinicalTrials.gov, NCT03525613) and Derby (NCT03525600) trials. There is no treatment-related data incorporated in the tool nor is this tool intended to make any treatment assessments or recommendations.

•  The risk calculator being presented is for illustrative purposes only. Patient disease experience and/or progression may vary and depends on many individual factors including, but not limited to, the patient’s clinical history.

Limitations

•  Patients enrolled in clinical trials are expected to differ from those seen in routine clinical practice on important risk factors, such as time from GA onset and other severity measures.

•  More frequent data collection during clinical trials (monthly) than routine practice (~quarterly) could impact estimates of time to event outcomes.

•  The risk calculator predicts 5-year outcomes. However, the rate of progression on these outcomes can change with time within those 5-years.

•  These calculated predictions do not guarantee onset of identified outcomes.

Proceed to GA Risk Calculator

Developed by Apellis Pharmaceuticals, Inc. in collaboration with The Cleveland Clinic Foundation

You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree